Scholarlink

Purpose <p>Nocardiosis is a rare but serious infection occurring predominantly in immunocompromised patients. The CLSI microdilution antimicrobial susceptibility testing is recommended for all nocardioses. Ready-to-use plates are available (Sensititre™ RAPMYCOI), but antimicrobials of interest (e.g. tedizolid, meropenem) are lacking. At the request of the French nocardiosis reference medical biology laboratory, a plate including meropenem and tedizolid was produced (Sensititre™ FRNOCAR1).</p> Methods <p>FRNOCAR1 was compared to RAPMYCOI using 133 clinical <i>Nocardia</i> isolates containing predominantly <i>N. farcinica</i> (23.3%), <i>N. cyriacigeorgica</i> (24.8%), and <i>N. nova</i> complex (21.1%). Acceptability was assessed using the FDA criteria (essential/category agreement; major, and very major error [VME] rates).</p> Results <p>All criteria were respected for 6 antimicrobials; for 5, the upper limit of the VME rate exceeded the criteria, despite a point estimate of 0.0%, due to a lack of resistant strains in the collection. For linezolid, the VME rate could not be calculated due to the absence of linezolid-resistant strains. Tedizolid minimal inhibitory concentration (MIC)50/MIC90 were 2–3 dilutions lower than that of linezolid (0.5/0.5&#xa0;µg/mL and 2/4 µg/mL, respectively). Imipenem was better than meropenem for <i>N. farcinica</i>; meropenem MIC was at least 2-dilutions lower than that of imipenem for <i>N. gamkensis</i> (8/8), <i>N. gipuzkoensis</i> (2/4), and <i>N. wallacei</i> (4/6).</p> Conclusion <p>For the antimicrobials common to both plates, the FRNOCAR1 demonstrated good agreement compared with RAPMYCOI. FRNOCAR1 includes tedizolid and meropenem, for which MIC could be reported upon justified request, with a comment indicating that these results are pending further validation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Nocardia antimicrobial susceptibility testing by microdilution: evaluation of ready-to-use plate including tedizolid and meropenem

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月4日

查看全文
  • Mateo Dutarte,
  • Charlotte Genestet,
  • Gérard Lina,
  • Oana Dumitrescu,
  • Elisabeth Hodille

摘要

Purpose

Nocardiosis is a rare but serious infection occurring predominantly in immunocompromised patients. The CLSI microdilution antimicrobial susceptibility testing is recommended for all nocardioses. Ready-to-use plates are available (Sensititre™ RAPMYCOI), but antimicrobials of interest (e.g. tedizolid, meropenem) are lacking. At the request of the French nocardiosis reference medical biology laboratory, a plate including meropenem and tedizolid was produced (Sensititre™ FRNOCAR1).

Methods

FRNOCAR1 was compared to RAPMYCOI using 133 clinical Nocardia isolates containing predominantly N. farcinica (23.3%), N. cyriacigeorgica (24.8%), and N. nova complex (21.1%). Acceptability was assessed using the FDA criteria (essential/category agreement; major, and very major error [VME] rates).

Results

All criteria were respected for 6 antimicrobials; for 5, the upper limit of the VME rate exceeded the criteria, despite a point estimate of 0.0%, due to a lack of resistant strains in the collection. For linezolid, the VME rate could not be calculated due to the absence of linezolid-resistant strains. Tedizolid minimal inhibitory concentration (MIC)50/MIC90 were 2–3 dilutions lower than that of linezolid (0.5/0.5 µg/mL and 2/4 µg/mL, respectively). Imipenem was better than meropenem for N. farcinica; meropenem MIC was at least 2-dilutions lower than that of imipenem for N. gamkensis (8/8), N. gipuzkoensis (2/4), and N. wallacei (4/6).

Conclusion

For the antimicrobials common to both plates, the FRNOCAR1 demonstrated good agreement compared with RAPMYCOI. FRNOCAR1 includes tedizolid and meropenem, for which MIC could be reported upon justified request, with a comment indicating that these results are pending further validation.